**METHODS** A retrospective review of a single site's experience with AVR was done. We looked at documentation/coding, post-operative admissions and the impact of the transfer penalty. From 11/2007 through 7/2012, 110 patients were coded with major complications of co-morbidities (220). We then looked at patients admitted to the post anesthesia unit (PACU) compared to the intensive care unit (ICU). 25 patients from 6/2013 through 12/2013 met protocol criteria and were admitted to the PACU and 62 to the ICU. We also analyzed the impact of the transfer policy of a sampling of 20 patients.

**RESULTS** The documentation review of the 110 patients coded with 220 revealed that 59(53%) had evidence which supported acute on chronic heart failure and may have been eligible for a major complication or co-morbidities (219) diagnosis related group (DRG). The post-operative admission demonstrated 25 patients admitted to the PACU with an average length of stay (LOS)  $4.42(\pm 4.46)$  days and the 62 patients admitted to the ICU average LOS was  $8.38(\pm 6.54)$  days. 38% of the PACU patients were coded with 219 and 33% with 220. The difference in weighed DRG is 2.6274units. The patients who were discharge where the transfer penalty applied had a greater than \$2000.00 loss per procedure.

**CONCLUSION** Advancement in healthcare comes with a price. In today's healthcare economy institutions continue to balance cost with being able to office the community the latest technology and treatment. This discussion suggests that there is cost saving opportunities however more research is needed to truly understand the impact.

#### CRT-803 TAVR in Patients with Liver Disease

Anoop M. Shah, Jeffrey Ogbara, Howard C. Herrmann, Zachary Fox, Mitul Kadakia, Saif Anwaruddin, Joseph E. Bavaria, Nimesh D. Desai, Dinesh Jagasia, Wilson Y. Szeto, Robert H. Li, Prashanth Vallabhajosyula, Jay Giri

Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA


**OBJECTIVE** Transcatheter Aortic Valve Replacement (TAVR) has emerged as an alternative to high-risk surgery in patients with comorbid conditions. The role of TAVR in patients with liver disease has not been fully examined.

**METHODS** We examined the procedural and intermediate to long-term follow-up outcomes of patients at our institution with aortic valve stenosis and chronic liver disease, identified by liver biopsy or from a combination of clinical findings. All patients were treated with Sapien or Sapien XT (Edwards Life Sciences, Irvine CA) balloon-expandable transcatheter bioprosthesis between Nov 2007 and Feb 2014.

**RESULTS** A total of 17 of 706 (2.41%) patients treated with transfemoral (TF) [n=14] or transapical (TA) [n=3] TAVR had liver disease (mean age 77.7±9.1 years, 10 men, mean STS score 8.4, mean MELD score 11.4, Child-Turcotte-Pugh (CTP) Class A [n=11], B [n=6], C [n=0]). Median follow-up was 466 days (range = 12-1403 days). In-hospital mortality was 5.88% and 90-day mortality was 17.65%. Safety and efficacy endpoints as defined by the Valve Academic Research Consortium (VARC) were significant for one perioperative death from a proximate cardiac cause (post-op day 14), one death after hospital discharge of unknown cause (post-op day 12), two deaths from non-cardiac causes (post-op days 50 and 487), and one death of unknown cause (post-op day 1005). There were no life-threatening or major bleeding complications. One patient had a myocardial infarction, one had a transient ischemic attack, and five had transient acute kidney injury.

**CONCLUSION** TF and TA TAVR are feasible methods in treating aortic stenosis in patients with liver disease. In patients with mild to moderate liver disease there are acceptable early and late complications, however, outcomes in patients with advanced liver disease (MELD > 20 or CTP class C) warrants further study.





Long term survival of patients with chronic liver disease after TAVR. \*Only 2 patients had follow up beyond 1000 days.

#### CRT-804

### Impact of Procedure Access on Early and Late Outcome of Severe Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Replacement

Edward Koifman, Sarkis Kiramijyan, Marco Magalhaes, Smita Negi, Ricardo Orlando Escarcega, Nevin Baker, Sa'ar Minha, Itsik Ben-Dor, Michael J. Lipinski, Sandeep Kumar, Zachary D. Jerusalem, Christian Shults, Paul J. Corso, Lowell Satler, Augusto Pichard, Rebecca Torguson, Ron Waksman MedStar Washington Hospital Center, Washington, DC


BACKGROUND Studies investigating the impact of procedural access on outcome of severe aortic stenosis (AS) patients undergoing transcatheter aortic valve replacement (TAVR) have shown conflicting results. Our aim was to characterize baseline differences between TAVR patients undergoing via transfemoral (TF) and transapical (TA) approaches, evaluate the risk for peri-procedural complications, and assess the impact of access type on early and late mortality.

**METHODS** Severe AS patients undergoing TAVR at our institution between May 2007 and July 2014 were included. Baseline demographic, clinical and imaging parameters were compared between TA and TF patients, peri-procedural complications rate were assessed as well as early and late mortality rates.

**RESULTS** Among 548 severe AS patients undergoing TAVR, TF approach was used in 428 and TA in 120. Main differences between the 2 groups consisted from lower BMI in the TA group along with a higher rate of peripheral vascular disease in comparison with the TF patients. Procedural data indicates shorter fluoroscopy time and smaller contrast volume in the TA group.

Complications rate were significantly higher in the TA group compared with TF group, with higher AKI rates (18% vs. 5%, p<0.001), major bleeding (15% vs. 6%, p=0.002), pleural effusion (23% vs. 4%, p<0.001) and atrial fibrillation (31% vs. 9%, p=0.004). In addition, an increased mortality rate at 30 days was noticed among the TA groups in comparison with TF patients (18% vs. 6%, p<0.001). However, mortality beyond 30 days revealed was similar among both groups (16% vs. 15%, p=0.73).

**CONCLUSION** TA approach TAVR portends increased risk for serious peri-procedural complications when compared with TF patients. TA patients have higher early mortality in comparison with TF patients; however, mortality rate is similar among patients surviving the procedure.



# CRT-805

## Long-Term Results: Following Transcatheter Aortic Valve Implantation

Pablo Codner, Abid Assali, Hana Vaknin-Assa, Gabriel Greenberg, Katia Orvin, Yaron Shapira, Alexander Sagie, Ran Kornowski

Rabin Medical Center, Petah Tikwa, Israel

**BACKGROUND** Transcatheter aortic valve implantation (TAVI) is the contemporary treatment of choice for high/prohibitive surgical risk patients with severe symptomatic aortic stenosis.

**METHODS** Outcomes of consecutive 275 (61% female) severe aortic stenosis patients, treated with TAVI and followed up to 3 years (mean 702 days), were analyzed and reported according to the Valve Academic Research Consortium 2 definitions. The primary end point was death from any cause.

**RESULTS** This patient group (60% women) was characterized by advanced age (mean  $81.7\pm6.8$ ), high mean logistic EuroScore =  $19.1\pm12$  and STS score =  $8.1\pm5$ . The